Author: James Love

As candidates, almost all democrats have promised voters, in several elections, they will support parallel trade in pharmaceuticals from Canada and other high income countries. As elected officials, nothing happens. President Obama already has authority to permit imports of medicines, if he wanted to exercise it. But not only is the White House not fullfillinbg the promise to allow imports, it has promised the CEO of PhRMA and several big companies that they won’t allow parallel trade in the health reform bill.

Continue Reading →

The Center for American Progress hosted a video conference of Dr. Howard Dean talking about Health Care reform on Tueday. The video is on the web here. On this one hour program, Howard Dean spends a little over 3 minutes responding to allegations that he is a “shill” for BIO, on the issue of biosimilars.

Continue Reading →

According to data from OpenSecrets.Org, from 1992 to 2006, Pfizer gave 74 percent of its campaign contributions to Republicans. Since then, particularly after Hank McKinnell left as CEO, Pfizer is giving slightly more to democrats than to republicans. In the current cycle, 54 percent of contributions go to democrats. Continue Reading →

The July 20, 2009 issue of BioCentury has an extensive report on the “Biosimilar fire Drill.” It discusses in detail the lobbying by the Biotechnology Industry Association (BIO, bio.org) to defeat efforts by President Obama, OMB, the FTC, Representative Waxman, Senator Brown, AARP, Public Citizen, PIRG, Consumers Union, KEI, Essential Action, and others, to reform the regulation to biologic medicines, so there is more generic competition. Continue Reading →

Congress should reject the 12-14.5 year monopoly for biologic products provided for in HR 1548

KEI* opposes H.R.1548, the bill to “establish a pathway for the licensure of biosimilar biological products,” on the grounds that the period of the monopoly is excessive, and not subject to safeguards that would protect consumers.

Continue Reading →

TACD has issued a resolution on copyright terms, and measures to mitigate the harm from excessive terms. The TACD Press release follows:

Continue Reading →

Apparently at least one entrant has qualified to win the $1 million Netflix grand prize. One can follow the progress of the teams on the Netflix Leaderboard: http://www.netflixprize.com/leaderboard.

Continue Reading →